Fungi in cystic fibrosis and non-cystic fibrosis bronchiectasis

Semin Respir Crit Care Med. 2015 Apr;36(2):207-16. doi: 10.1055/s-0035-1546750. Epub 2015 Mar 31.

Abstract

Bronchiectasis is a pathologic bronchial dilatation with loss of function that can result from multiple inflammatory and infectious injuries to the conducting airways of the lung. Molds, particularly the filamentous fungus Aspergillus fumigatus, have been implicated as a common cause of both cystic fibrosis (CF) and non-CF bronchiectasis, the latter primarily in patients with severe asthma. The pathogenesis of mold-associated bronchiectasis is usually due to atopic sensitization to mold allergens in the presence of active chronic endobronchial fungal infection with host innate and adaptive immune deviation to a Th2-dominated inflammation, a condition known as allergic bronchopulmonary aspergillosis (ABPA) (or allergic bronchopulmonary mycosis if a non-Aspergillus mold is implicated). Diagnostic criteria of ABPA continue to evolve, while treatment relies upon downregulation of the allergic inflammatory response with immunomodulatory agents and antifungal pharmacotherapy.

Publication types

  • Review

MeSH terms

  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use
  • Aspergillosis / drug therapy*
  • Aspergillosis, Allergic Bronchopulmonary / diagnosis*
  • Aspergillosis, Allergic Bronchopulmonary / drug therapy
  • Aspergillus fumigatus / pathogenicity*
  • Bronchiectasis / diagnosis
  • Bronchiectasis / microbiology*
  • Bronchiectasis / therapy
  • Cystic Fibrosis / diagnosis
  • Cystic Fibrosis / microbiology*
  • Cystic Fibrosis / therapy
  • Humans
  • Hypersensitivity
  • Immunoglobulin E / blood
  • Triazoles / therapeutic use

Substances

  • Antifungal Agents
  • Triazoles
  • Immunoglobulin E
  • Amphotericin B